GSMA RCS Messaging Initiative Takes off as Multiple Global Operators Interconnect Networks
The GSMA today announced that mobile operators América Móvil, Rogers Communications and Sprint have interconnected their networks across the Americas, while Deutsche Telekom, Telenor Group, Telia Company and Vodafone Group have interconnected in Europe, enabling subscribers in these regions to access advanced Rich Communications Services (RCS) across 22 networks in 17 countries1. The upgraded service will enable users to enjoy enhanced messaging services such as chat, group chat and file share amongst many others.
Initial interconnection was achieved using the Jibe RCS Hub from Google, as well as a direct interconnect between Vodafone and Deutsche Telekom in Germany. In parallel, leading operators including Bell Canada, China Mobile, Deutsche Telekom and T-Mobile US are working on a joint initiative together with Samsung and Syniverse to accelerate the open ecosystem of RCS Interconnection Hubs. Efforts like this initiative to promote an open interconnected RCS ecosystem are also supported by AT&T and Swisscom. Interconnection Hubs will be fundamental for the rapid user adoption of RCS.
“In the space of a year we have aligned the industry behind a single, interoperable profile, which has resulted in a significant number of operator launches and a rapidly growing monthly user base. Now we are seeing operators further demonstrate their support for RCS by interconnecting their networks in a connect-once-to-all manner, which will dramatically increase the number of contacts a subscriber can enjoy RCS messaging with,” said Alex Sinclair, Chief Technology Officer, GSMA. “We are also moving quickly towards RCS business messaging, a new area offering the opportunity for brands to engage directly with their customers in a more interactive way. This is an exciting time for the global RCS community and we look forward to seeing more launches and interconnections in the near future.”
Interconnection of additional operators and hub providers is expected to follow and the number of network interconnections forecast to exceed 140 by the end of March 2018. Momentum for RCS is growing around the world with over 159 million current active monthly users, and the potential for continued growth is also significant with GSMA Intelligence estimating that, by Q4 2018, there will be 350 million users.
“As operator roll-outs of advanced Messaging (RCS) gather pace around the world, interconnecting the networks of launched operators becomes a key success metric,” said Dr. Petja Heimbach of Deutsche Telekom Group and Chair of the GSMA’s IP Comms Group. “Having a number of interconnect hubs, which are themselves interconnected, is the fastest way to accelerate the establishment of global RCS interconnect. We are hoping to see first commercially available offers in the second half of 2018.”
The GSMA Universal Profile for Advanced Messaging
The GSMA’s Universal Profile (UP) provides an open, consistent and global messaging service across networks and devices. It simplifies interoperability and enables OEMs and OS providers to achieve scale and give consumers a richer and more consistent messaging experience regardless of device or network. UP is currently backed by over 70 leading operators, vendors and OS providers worldwide. Philippines based, Globe Telecom also became one of the first operators to launch RCS in the Asia Pacific region this month.
UP 2.0 upgrades the service further by enabling Application-to-Person RCS Business messaging and RCS-capable chatbots, as well as additional messaging expressiveness features. It introduces ‘conversational commerce’ that will enable users to interact with brands within the platform. It is an important step that when combined with network interoperability enables operators to offer a consistent and engaging messaging experience. For more information about the RCS Universal Profile or to download the Universal Profile specification 2.0, please go to: www.gsma.com/futurenetworks/ip-services/universal-profile/.
The GSMA Future Networks Programme at MWC 2018
The GSMA Future Networks programme will host a number of seminars on 5G and Messaging as a Platform (MaaP) at MWC 2018. They will also be showcasing a number of interactive demonstrations at the GSMA Innovation City in Hall 4. For further information on all these activities, visit www.gsma.com/futurenetworks/events-and-webinars/new-mobile-world-congress-2018-barcelona/.
Notes to Editors
|In Europe: Albania, (VF, DT); Czech (VF); Germany (VF); Greece (VF, DT); Hungary (VF); Ireland (VF); Italy (VF); Norway (Telenor, Telia); Portugal (VF); Romania (VF, DT); Slovakia (DT); Spain (VF); Sweden (Telia); Turkey (VF) and United Kingdom (VF). In the Americas: Canada (Rogers); USA (Sprint); Mexico (America Movil)|
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06 | Pressemelding
Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an
STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00 | Pressemelding
Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe
Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53 | Pressemelding
Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and
CES Asia: Innovation at the Speed of 5G15.6.2018 14:59 | Pressemelding
CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re
bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00 | Pressemelding
bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m
bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00 | Pressemelding
bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch